Impact News +++ Applied Digital Advances AI Factory Buildout with Second $787.5 Million Draw from Macquarie Asset... (GlobeNewswire EN) +++ APPLIED DIGITAL Aktie -3,06%

ALTIMMUNE Aktie

>ALTIMMUNE Aktienkurs

3.668 EUR -0.6% (Tradegate)

Ask: 3.659 EUR / 5500 Stück

Bid: 3.63 EUR / 5600 Stück

Tagesumsatz: 326 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

ALTIMMUNE Aktie über LYNX handeln

Intraday

1 Jahr

>ALTIMMUNE Performance

1 Woche: +9,1%

1 Monat: +6,3%

3 Monate: +25,0%

6 Monate: -26,8%

1 Jahr: -45,9%

laufendes Jahr: -49,9%

>ALTIMMUNE Aktie

Name:

ALTIMMUNE INC. DL-,0001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US02155H2004 / A2N5Z6

Symbol/ Ticker:

3G0 (Frankfurt) / ALT (NASDAQ)

Kürzel:

FRA:3G0, ETR:3G0, 3G0:GR, NASDAQ:ALT

Index:

Webseite:

https://altimmune.com/

Profil:

Altimmune, Inc. is a biopharmaceutical company eng..
>Volltext..

Marktkapitalisierung:

386.12 Mio. EUR

Unternehmenswert:

219.79 Mio. EUR

Umsatz:

0.02 Mio. EUR

EBITDA:

-78.11 Mio. EUR

Nettogewinn:

-72.55 Mio. EUR

Gewinn je Aktie:

-0.92 EUR

Schulden:

13.75 Mio. EUR

Liquide Mittel:

52.98 Mio. EUR

Operativer Cashflow:

-57.63 Mio. EUR

Bargeldquote:

16.72

Umsatzwachstum:

-63.51%

Gewinnwachstum:

23.09%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Div. Historie:

20.01.17 - 224502.93€

Insiderhandel:

Suchwörter:

ALTIMMUNE

Letzte Datenerhebung:

12.11.25

>ALTIMMUNE Kennzahlen

Aktien/ Unternehmen:

Aktien: 104.34 Mio. St.

Frei handelbar: 99.21%

Leerverk. Aktien: 24.68%

Rückkaufquote: -27.43%

Mitarbeiter: 59

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Buy

Kursziel: 326.26%

Bewertung:

KGV: -

KGV lG: -

KUV: 17087.17

KBV: 2.2

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -495%

Gewinnmarge: -419575%

Operative Marge: -452310%

Managementeffizenz:

Gesamtkaprendite: -45.82%

Eigenkaprendite: -52.61%

>ALTIMMUNE Peer Group

Es sind 597 Aktien bekannt.

>ALTIMMUNE Chart & Kurs - NASDAQ

>ALTIMMUNE News

12.11.25 - 17:24	Altimmune auf der Stifel 2025 Healthcare Conference: Strategische Einblicke zu Pemvidutid (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

11.11.25 - 16:12	Altimmune releases additional phase 2 pemvidutide data for MASH (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

11.11.25 - 14:54	Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025 (GlobeNewswire EN)
	24-week data demonstrated significant MASH resolution and weight loss, and strong evidence of anti-fibrotic activity with a favorable tolerability profile...

07.11.25 - 14:06	Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025 (GlobeNewswire EN)
	AI-based digital pathology analysis provides high-resolution quantification of hepatic fibrosis and objective measurement of fibrosis improvement...

06.11.25 - 20:30	Altimmune outlines flexible Phase III design and regulatory milestones while strengthening leadership (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

06.11.25 - 13:12	Altimmune GAAP EPS of -$0.21 beats by $0.05, revenue of $0.05M beats by $0.05M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

05.11.25 - 16:03	Altimmune Q3 2025 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

05.11.25 - 13:33	Altimmune to Participate in Two Upcoming Investor Conferences (GlobeNewswire EN)
	GAITHERSBURG, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company's management team will participate and be available for one-on-one meetings at the following investor conferences:...

03.11.25 - 13:33	Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder (GlobeNewswire EN)
	Enrollment completed ahead of schedule, underscoring strong interest from patient community in a potential new therapeutic option...

30.10.25 - 12:33	Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025 (GlobeNewswire EN)
	GAITHERSBURG, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it will report its third quarter 2025 financial results on Thursday, November 6, 2025....

20.10.25 - 13:33	Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025 (GlobeNewswire EN)
	Oral presentation to highlight 24-week efficacy and safety data...

10.10.25 - 14:33	Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) (Benzinga)
	Latest Ratings for ALT DateFirmActionFromTo Jun 2021B. Riley SecuritiesMaintainsBuy Jun 2021JMP SecuritiesMaintainsMarket Outperform Jun 2021HC Wainwright & Co.MaintainsBuy View More Analyst Ratings for ALT View the Latest Analyst Ratings read more...

07.10.25 - 13:27	ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm (PR Newswire)
	LOS ANGELES, Oct. 7, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Altimmune, Inc. ("Altimmune" or "the Company") (NASDAQ: ALT) for violations of §§10(b) and 20(a) of the Securities Exchange Act......

06.10.25 - 14:48	The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc.(ALT) Shareholders (PR Newswire)
	NEW YORK, Oct. 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT). Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.......

03.10.25 - 16:06	INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT (PR Newswire)
	NEW YORK, Oct. 3, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW),......

03.10.25 - 15:54	SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune (PR Newswire)
	Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Altimmune between August 10, 2023 and June 25, 2025 and would like to......

02.10.25 - 22:03	ALT Deadline: ALT Investors with Losses in Excess of $50K Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit (PR Newswire)
	NEW YORK, Oct. 2, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025, both dates inclusive (the "Class Period"), of the important October 6, 2025 lead plaintiff......

02.10.25 - 14:01	ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm (PR Newswire)
	LOS ANGELES, Oct. 2, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Altimmune, Inc. ("Altimmune" or "the Company") (NASDAQ: ALT) for violations of §§10(b) and 20(a) of the Securities Exchange Act......

01.10.25 - 14:15	Altimmune, Inc. (NASDAQ: ALT) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit (PR Newswire)
	PHILADELPHIA, Oct. 1, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Altimmune Inc. (NASDAQ: ALT) ("Altimmune" or the "Company") on behalf of investors who purchased or otherwise acquired publicly traded securities of......

30.09.25 - 22:45	ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm (PR Newswire)
	LOS ANGELES, Sept. 30, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Altimmune, Inc. ("Altimmune" or "the Company") (NASDAQ: ALT) for violations of §§10(b) and 20(a) of the Securities Exchange......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Die einzigen friedlichen Einfälle sind die des Geistes und des Lichtes. - Dr. Fritz P. Rinnhofer

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram